Form 4: Boundless Bio Executive Acquires Stock Options
SEC Form 4 Filing
Christian Hassig, Chief Scientific Officer of Boundless Bio, Inc., acquired stock options on March 27, 2024.
Summary
- On March 27, 2024, Christian Hassig, the Chief Scientific Officer of Boundless Bio, Inc., acquired 48,703 stock options.
- The options have an exercise price of $16.
- The stock options vest in 48 substantially equal monthly installments beginning on April 27, 2024.
- The options expire on March 26, 2034.
- Following the transaction, Hassig directly owns 48,703 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is a neutral event.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for executives to receive stock options as part of their compensation package.
Stakeholder Impact
- The granting of stock options aligns the executive's interests with those of the shareholders, potentially incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction: Christian Hassig acquired stock options. |
| 04/27/2024 | Vesting start date: Stock options vest in 48 substantially equal monthly installments beginning on this date. |
| 03/26/2034 | Expiration date: Stock options expire on this date. |
| 03/29/2024 | Date of filing: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.